Top Markets
#1 MowCat MowCat +631.35%
#2 龙虾 (Lobster) 龙虾 (Lobster) +79.42%
#3 Magma Finance Magma Finance +40.29%
#4 DeXe DeXe +35.60%
#5 Akedo Akedo +28.32%
#6 Cortex Cortex +23.99%
#7 SIXSEVEN SIXSEVEN +22.24%
#8 MarsCoin MarsCoin +18.02%
#9 OpenEden OpenEden +16.05%
#10 Pons Pons +15.08%
Coin of the day
MowCat MowCat
Tetapan
Bahasa
MALAY
Mata wang
USD
Tema
Staidson (Beijing) BioPharmaceuticals Co., Ltd. Staidson (Beijing) BioPharmaceuticals Co., Ltd.

Staidson (Beijing) BioPharmaceuticals Co., Ltd.

300204
Kedudukan dalam Saham #7948
Staidson (Beijing) BioPharmaceuticals Co., Ltd. is a Chinese biopharmaceutical... Staidson (Beijing) BioPharmaceuticals Co., Ltd. is a Chinese biopharmaceutical company that specializes in the entire lifecycle of therapeutic drugs, from research and development to production and market distribution. Their product portfolio encompasses a variety of drug types, including advanced protein-based medicines like therapeutic monoclonal antibodies, innovative gene and cell therapies, and conventional chemical pharmaceuticals. The company's primary therapeutic areas address conditions related to the nervous system, infectious diseases, gastrointestinal health, the urinary system, and autoimmune disorders. Notably, Staidson has established a strategic partnership with Pivotal S.L. to conduct clinical trials in Europe for BDB-001, a monoclonal anti-C5a antibody, aimed at treating patients with severe, progressive COVID-19 caused by the SARS-CoV-2 virus. Founded in 2002, the company's headquarters are located in Beijing, China.
Harga Saham
$3.11
Modal Pasaran
$1.41B
Perubahan (1 hari)
-1.97%
Perubahan (1 tahun)
-57.22%
Negara
CN
Perdagangan Staidson (Beijing) BioPharmaceuticals Co., Ltd. (300204)

Kategori

Healthcare
Hasil untuk Staidson (Beijing) BioPharmaceuticals Co., Ltd. (300204)
Hasil pada Aug 2026 TTM: 0
Menurut laporan kewangan terkini daripada Staidson (Beijing) BioPharmaceuticals Co., Ltd., hasil semasa syarikat (TTM) ialah 0. Pada tahun 2026, syarikat memperoleh hasil sebanyak 0 sama dengan hasil pada tahun 2026 iaitu 0. Hasil ialah jumlah pendapatan keseluruhan yang dijana oleh syarikat daripada jualan barangan atau perkhidmatan. Tidak seperti keuntungan, tiada perbelanjaan ditolak.
Sejarah hasil bagi Staidson (Beijing) BioPharmaceuticals Co., Ltd. dari 2026 hingga 2026
Hasil pada akhir setiap tahun
Tahun Hasil Ubah
Tidak cukup data untuk tarikh yang disediakan.
Hasil untuk syarikat atau pesaing serupa
Syarikat Hasil Perbezaan Hasil Negara
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 $12.62B -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 $6.02B -
NL
CSL Limited CSL Limited
CSL Limited
CSL.AX
 $15.74B -
AU
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 $2.23B -
US
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH